sb 203580 has been researched along with Leukemia L 1210 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonavita, F; Facchini, A; Flamigni, F; Stanic, I; Stefanelli, C; Tantini, B | 1 |
| Barancík, M; Bohácová, V; Breier, A; Hudecová, S; Krizanová, O; Kvackajová, J | 1 |
2 other study(ies) available for sb 203580 and Leukemia L 1210
| Article | Year |
|---|---|
Control of survival of proliferating L1210 cells by soluble guanylate cyclase and p44/42 mitogen-activated protein kinase modulators.
Topics: Animals; Apoptosis; Caspases; Cell Division; Cell Survival; Cyclic GMP; Enzyme Activation; Enzyme Inhibitors; Guanylate Cyclase; Imidazoles; Leukemia L1210; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Oxadiazoles; Oxidation-Reduction; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinoxalines; Signal Transduction; Tumor Cells, Cultured | 2001 |
SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cytosol; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Imidazoles; Leukemia L1210; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Signal Transduction; Tumor Cells, Cultured; Vincristine | 2001 |